We sought to determine the influence of preoperative oral midazolam on 1) sedation score, 2) measures of anesthetic emergence, 3) recovery times, and 4) bispectral index (BIS) measurements during sevoflurane/N 2 O anesthesia in adolescent patients. Fifty ASA I and II patients 10 -18 yr of age were enrolled in a prospective double-blinded study. Patients were randomized to receive either 20 mg of midazolam (M group) or midazolam vehicle (P group) as premedication. Before the induction, sedation scores and BIS values were determined in all patients. After inhaled induction and intubation, expired sevoflurane was stabilized at 3% in 60% N 2 O and the corresponding BIS (BIS I) recorded. Upon completion of surgery, sevoflurane was stabilized at 0.5% and the BIS (BIS E) again recorded. Plasma midazolam levels were measured at the time of BIS I and BIS E. There were no significant differences between groups in awakening time, sevoflurane/N 2 O awakening concentrations, time to postanesthesia care unit discharge, or BIS I and BIS E measurements. Sedation scores and preinduction BIS values were significantly lower in Group M than in Group P, although only 40% of midazolam-treated patients exhibited detectable sedation, with marked interindividual variability in achieved plasma midazolam levels. Detectable preoperative sedation was predictive of delayed emergence.
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M
idazolam is the most commonly ordered premedication in pediatric anesthesia practice. More than 85% of anesthesiologists responding to a national survey of premedication practices conducted by Kain et al. (1) indicated that they prescribed midazolam when they chose to premedicate. The benefits of effective premedication include a reduction in both patient and parental separation anxiety, partial anterograde amnesia, facilitation of a smooth anesthetic induction, and a reduction in reported undesirable postoperative behavioral changes (2, 3). There are numerous published reports documenting the safety and efficacy of oral midazolam premedication in children from 1 to 12 yr of age (4 -12) . However, similar investigations in the adolescent population have not been conducted. We evaluated the effect of 20 mg of oral midazolam premedication in healthy adolescent surgical patients by using the Observer's Assessment of Alertness/Sedation Scale (OAA/S) (13) and the bispectral index (BIS). We further sought to determine the effect of oral midazolam on 1) intraoperative BIS measurements during fixed levels of sevoflurane administration, 2) emergence and recovery times, and 3) midazolam plasma levels at two specified intervals after administration.
Methods
In accordance with an IRB approved protocol that included informed consent, ASA I and II pediatric patients ages 10 -18 yr and weighing from 40 to 100 kg anticipated to undergo surgical procedures lasting Ͻ90 min were enrolled in a prospective, randomized, and double-blinded study. Exclusion criteria included 1) known adverse reaction to benzodiazepines, 2) use of sedative/hypnotic, narcotic, anticonvulsant, stimulant, or other medications reported to affect the minimum alveolar anesthetic concentration (MAC) of inhaled anesthetics within the previous month, and 3) the presence of neurologic, renal, or hepatic disease. Patients were randomized to receive 20 mg of oral midazolam at a concentration of 2 mg/mL (Group M) or midazolam vehicle (Syrpaltaâ syrup; Humco Labs, Texarkana, TX) as placebo (Group P) 15 Anesthesia was then induced with 8% sevoflurane in 60% N 2 O. IV access was established and endotracheal intubation performed after the administration of a nondepolarizing neuromuscular-blocking drug. Gas concentrations were analyzed by a Capnomac Ultima™ gas analyzer (Datex Medical Instrumentation, Inc., Helsinki, Finland). End-tidal sevoflurane and N 2 O concentrations were then adjusted to 3% (Ϯ0.2%) and 60% (Ϯ2%), respectively, at normocapnia (ETco 2 , 35-45 mm Hg) and maintained constant for 5 min before recording the associated postinduction BIS value (BIS I). Anesthesia was maintained with sevoflurane in 60% N 2 O, adjusted as necessary to hemodynamic variables but not titrated to BIS. At the completion of surgery, end-tidal sevoflurane and N 2 O concentrations were adjusted to 0.5% (Ϯ0.05%) and 60% (Ϯ2%), respectively, and again maintained constant for 5 min before recording the preemergence BIS (BIS E). Although a 5-min period of sevoflurane stabilization is insufficient to allow complete equilibration, it was sufficient to achieve stable BIS readings. BIS measurements were recorded at 5-s intervals for 1 min and averaged to obtain a single value. Blood specimens for the purpose of determining plasma midazolam levels were collected at the time BIS I and BIS E measurements were obtained. Plasma levels were determined with gas chromatography/mass spectrometry by National Medical Services, Inc. (Willow Grove, PA). Results are reported as nanograms per milliliter.
After determination of the BIS E and confirmation of the return of normal neuromuscular function, inhaled anesthetics were discontinued, and 100% oxygen was delivered through the system at a standard flow of 5 L/min. Time to awakening (as evidenced by eye opening, active facial grimace, or purposeful movement in response to a jaw thrust maneuver) was measured to the nearest 30 s. End-tidal sevoflurane concentration, end-tidal N 2 O concentration, and BIS at awakening were recorded. No study patient received intraoperative narcotics, but narcotics were administered immediately upon emergence for those procedures in which such a need could be reasonably anticipated. Ketorolac and local anesthetic blocks were used as appropriate.
All determinations of awakening time were made by one of two attending anesthesiologists responsible for the study. The anesthesiologist determining awakening time was blinded to grouping and monitoring and had no contact with the patient before surgery or during the induction. Monitoring and data recording were performed by the other investigator. In addition to emergence measurements, time to postanesthesia care unit (PACU) discharge readiness, as assessed on a modified (to include pulse rate and temperature) 16-point Aldrete scale (14), was recorded and compared between groups. All PACU assessments were made by a single trained observer blinded to grouping.
Statistical analysis was performed with MINITAB Statistical Software, Release 12 (Minitab, Inc., State College, PA). Demographic data, preoperative and operative time intervals, and drug concentrations were analyzed with two-tailed Student's t-tests. Results are reported as the mean Ϯ sd. Sedation scores, BIS measurements, and recovery times were compared by using the Mann-Whitney U-test. Results are reported as the median and range. The number of patients with a measurable sedative response (defined as an OAA/S score of 17 or less) in each group was compared by using Fisher's exact test. The Pearson correlation was used to test for the relationships between drug levels, weights, and ages. The Spearman rank correlation was used to test for relationships involving ordinal data or nonnormally distributed data sets. A P value Ͻ0.05 was considered significant.
The relationship between plasma midazolam concentration and OAA/S score was analyzed by nonlinear regression (Fig. 1) . A logistic model was applied in which it was postulated that the probability of an OAA/S score of Ͻ18 was given by the following equation: probability ϭ C␣/(C␣ ϩ C 50␣ ). Values of ␣ and C 50 were estimated by logistic regression with NONMEM statistical software (15) . C is the observed plasma concentration and C 50 the concentration at which 50% of subjects are expected to demonstrate a positive response.
Results
There were 50 patients in the final analysis: 25 in Group P and 25 in Group M. The study groups were comparable with respect to age (Group P, 14.4 Ϯ 2.1 yr; Group M, 14.4 Ϯ 2.4 yr), weight (Group P, 57.6 Ϯ 12.6 kg; Group M, 60.9 Ϯ 13.9 kg), sex distribution (15 males and 10 females in both groups), and procedure duration (Group P, 72 Ϯ 26 min; Group M, 66 Ϯ 27 min).
Preinduction OAA/S scores and BIS values were obtained in all patients immediately before the induction of general anesthesia. The time from the administration of midazolam to OAA/S and BIS assessment was 29.0 Ϯ 4.8 min (range, 23-40 min.). The median preinduction BIS was significantly lower (P Ͻ 0.001) in Group M (92; range, 67-98) than in Group P (97; range, 89 -98). Ten of 25 Group M patients exhibited clinically detectable sedation, whereas only 1 of 25 placebo patients was measurably sedated (P Ͻ 0.001). BIS in the 10 midazolam patients demonstrating sedative effect was further reduced, with a median value of 82. The median preinduction OAA/S score was also significantly lower (P Ͻ 0.002) in Group M (18; range, 12-20) than in Group P (20; range, [17] [18] [19] [20] . There was a significant correlation between preinduction BIS and OAA/S score (r ϭ 0.542, P Ͻ 0.006) (Fig. 2) . One patient in each group reported Ͻ4 h sleep the night before surgery. The single placebo patient with detectable sedative effect (OAA/S of 17) reported 3.5 h sleep. The single midazolam patient reporting Ͻ4 h sleep had an OAA/S score of 13 and a postinduction plasma midazolam level of 49 ng/mL. The average reported hours of sleep were 6.8 Ϯ 1.8 h and 6.5 Ϯ 1.6 h in the Group P and Group M, respectively; these were not significantly different.
Intraoperative data obtained from the entire study group are displayed in Table 1 . The awakening time (interval from anesthetics off to emergence and extubation) and the end-tidal concentrations of sevoflurane/ N 2 O at awakening were not different between treatment groups. The time intervals between induction of anesthesia and acquisition of BIS I measurements were 16.5 Ϯ 3.1 min (Group M) and 15.2 Ϯ 2.7 min (Group P). The time intervals from induction to measurement of BIS E were 62.3 Ϯ 27.8 min (Group M) and 69.6 Ϯ 26.4 min (Group P). Neither pair of intervals is statistically different, indicating similar cumulative drug exposure in each group at the times these determinations were made. There were no statistically significant differences between groups in BIS I or BIS E measurements. Furthermore, there was no difference in intraoperative BIS measurements between patients with detectable preoperative sedation and those without. The median BIS values at awakening, however, were lower (P Ͻ 0.006) in Group M (83; range, 68 -97) than in Group P (92; range, 59 -98).
Plasma midazolam levels were available in 24 of 25 Group M patients. Specimen mishandling resulted in the loss of data from one patient. In Group M, the mean midazolam level was 49 Ϯ 31 ng/mL at BIS I and 32 Ϯ 24 ng/mL at BIS E. There was no significant correlation between simultaneous midazolam levels and BIS values. With use of logistic regression, the C 50 value for an OAA/S score of Ͻ18 was 51.4 ng/mL (se Ϯ 8.2). The value of ␣ (the variable determining the steepness of the concentration-effect curve) was determined to be 3.57 (se Ϯ 1.24). The resultant probability curve and the distribution of the sedative response versus the corresponding plasma midazolam concentration are displayed in Figures 1 and 3 .
There was no correlation between plasma midazolam levels or sedation score and patient weight. However, there was a weak (r ϭ Ϫ0.398, P Ͻ 0.05) but significant negative correlation between midazolam level and patient age. The correlation between age and sedation score approached, but did not reach, statistical significance (P Ͻ 0.09).
In Group M, preoperative OAA/S score correlated significantly with emergence time (r ϭ Ϫ0.566, P Ͻ 0.004) (Fig. 2 ), but not with time to PACU discharge readiness. Considering all patients, emergence time was 2.3 Ϯ 1.0 min in patients with OAA/S scores of 18 -20 and 4.0 Ϯ 1.1 min in patients with scores Ͻ18 (P Ͻ 0.001). Within Group M, emergence time was 2.2 Ϯ 1.1 min and 4.0 Ϯ 1.1 min for these same sedation ranges (P Ͻ 0.001). Neither the midazolam level at BIS E nor the BIS E value correlated with emergence time or PACU discharge time. The median time to PACU discharge readiness was 10 min (range, 5-82 min) in Group P and 11 min (range, 7-54 min) in Group M; these times were not significantly different.
Parenteral narcotics were administered after surgery as indicated on the order of the attending anesthesiologist. Fourteen midazolam-and 15 placebopremedicated patients received narcotics in the postoperative period.
Discussion
BIS correlates with midazolam-induced sedation in healthy adults receiving IV midazolam, as assessed by the responsiveness subscale of the OAA/S (16) . In this study of preadolescent and adolescent patients, a clinically detectable sedative effect as measured by this scale Figure 1 . Concentration-effect probability curve for midazolaminduced sedation. P (enclosed equation) is the probability of an Observer's Assessment of Alertness/Sedation scale score Ͻ18 at the corresponding plasma midazolam concentration. C is the observed midazolam concentration; 51.4 mg/mL is the concentration at which a 50% response is predicted.
was evident in only 40% of those individuals receiving 20 mg of oral midazolam as anesthetic premedication. Both preoperative OAA/S score and BIS were significantly lower in our midazolam-premedicated patients and were significantly correlated with each other (Fig. 2) . BIS was further reduced in the 40% of patients with measurable sedative effect.
Our initial midazolam levels were obtained at an average of 45 minutes after the administration of the drug. The mean plasma level at this acquisition (49 ng/mL) corresponds to that reported by Marshall et al. (17) (42 ng/mL) in pediatric patients receiving oral midazolam and achieving a similar sedative effect. This level, however, is only approximately half that reported by Malinovsky et al. (18) in pediatric patients receiving 0.5 mg/kg of oral midazolam, and it is slightly less than 58 ng/mL 45 minutes after a 0.45 mg/kg oral dose as reported by Payne et al. (19) . This may in part be attributable to the smaller average per kilogram dose in our patients (0.33 mg/kg), differences in drug formulation, age-related pharmacokinetic differences, differences in sample acquisition time, or a combination of these. Because of the study design, midazolam levels were obtained simultaneously with BIS measurements in an effort to determine whether or not plasma midazolam concentration had a detectable effect on intraoperative BIS, and it did not. As a result, the plasma midazolam concentrations and OAA/S scores used to construct the concentration-effect curve (Fig. 1) were not obtained simultaneously. The sedation assessment preceded the corresponding midazolam level by approximately 15 minutes, and the curve should be interpreted accordingly. In our patients, three general categories of sedative effect and corresponding plasma level are evident, consistent with the reported adult threshold level for sedation of 40 ng/mL (20) and suggesting a similar pharmacodynamic response to that of adults. At Ͻ40 ng/mL a sedative effect did not occur. Between 40 and 80 ng/mL, the sedative response shows significant interindividual variability, with nearly equal numbers of patients in each response group. At Ͼ80 ng/mL, detectable sedation is the expected result (Fig. 3) . These results suggest significant pharmacokinetic and pharmacodynamic variability in this population; this variability is also characteristic of adults receiving midazolam.
There was a weak but significant negative correlation between patient age and midazolam level which was independent of body weight. This suggests a maturational change in midazolam pharmacokinetics during the course of adolescence and suggests that their pharmacokinetic handling of midazolam is transitional between that of childhood and adulthood.
Preoperative midazolam had no influence on either of the two intraoperative BIS measurements (Table 1) . It seems that at this midazolam dose, the hypnotic effect of sevoflurane/N 2 O overwhelms any potential contribution of midazolam to BIS. No additive or synergistic effect was detectable, even among those individuals who exhibited detectable sedation before induction. This is in contrast to the effect reported by Denman et al. (21) , who demonstrated that methohexital given as premedication to pediatric surgical patients does significantly decrease BIS during sevoflurane/N 2 O anesthesia.
If one considers each study group as a whole, midazolam premedication does not prolong emergence time or time to PACU discharge readiness. However, the preoperative OAA/S score was significantly correlated with emergence time (Fig. 2) . The emergence time in patients manifesting a detectable sedative effect after premedication was Ͼ70% longer than in those without detectable sedation. The lack of a similar effect on time to PACU discharge suggests that this residual effect is insufficient in magnitude, duration, or both to influence this measure of recovery. Neither midazolam administration nor the preinduction OAA/S score correlated with emergence concentrations of anesthetic gases.
It should be noted that our reported awakening concentration of sevoflurane is quite different than the reported MAC-awake of sevoflurane in children (22) , and it was not our intention to attempt to define MAC-awake in this population. Awakening concentrations reported in this study (Table 1) were measured in combination with residual N 2 O, and our washout technique does not conform to either the fast or slow alveolar washout techniques often used in the determination of MAC-awake values for volatile anesthetics (23). Our range of BIS values recorded at the time of awakening (59 -98) is comparable to that recorded at the time of eye opening in adult patients receiving propofol/alfentanil/N 2 O anesthesia (24) , and it is comparable to those recorded in a series of pediatric patients recovering from general anesthesia (25) . We speculate that the decreased BIS at awakening in midazolam-treated patients (Table 1 ) may be a manifestation of residual midazolam sedative effect similar to that evident in sedate, conscious patients just before the induction (preinduction BIS). Although the hypnotic effect of sevoflurane is sufficient to overwhelm the effect of midazolam on BIS during surgery, a small but detectable effect of midazolam may again become evident when the influence of sevoflurane dissipates and consciousness is restored.
In conclusion, we demonstrated that, in a sample of healthy adolescents receiving 20 mg of oral midazolam, Ͻ50% manifested clinically detectable sedation. Preinduction BIS was significantly lower in midazolamtreated patients, was lower yet in patients who manifested a detectable sedative response, and was significantly correlated with simultaneous OAA/S score. However, intraoperative BIS measured at two fixed levels of sevoflurane administration was not affected by midazolam premedication. In aggregate, midazolam premedication did not prolong emergence from general anesthesia, did not affect the expired concentration of sevoflurane/N 2 O at emergence, and did not prolong time to PACU discharge readiness. Emergence time was significantly prolonged in patients who manifested clinically detectable sedation, and it is the presence of a detectable sedative effect that should be considered when anticipating possible effects of midazolam on awakening. This residual effect was insufficient to influence discharge time from the PACU.
